Document Detail


Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy.
MedLine Citation:
PMID:  22294629     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVES: The objective of this study was to evaluate the rates of previously undiagnosed rheumatic diseases during the first trimester of pregnancy and their impact on the pregnancy outcome.METHODS: Pregnant women in their first trimester were screened using a two-step approach using a self-administered 10-item questionnaire and subsequent testing for rheumatic autoantibodies (antinuclear antibody, anti-double-stranded DNA, anti-extractable nuclear antigen, anticardiolipin antibodies, anti-β2-glycoprotein I antibodies and lupus anticoagulant) and evaluation by a rheumatologist. Overall, the complications of pregnancy evaluated included fetal loss, pre-eclampsia, gestational diabetes, fetal growth restriction, delivery at less than 34 weeks, neonatal resuscitation and admission to the neonatal intensive care unit.RESULTS: Out of the 2458 women screened, the authors identified 62 (2.5%) women with previously undiagnosed undifferentiated connective tissue disease (UCTD) and 24 (0.98%) women with previously undiagnosed definite systemic rheumatic disease. The prevalences were seven (0.28%) for systemic lupus erythematosus and Sjogren's syndrome, six (0.24%) for rheumatoid arthritis, three (0.12%) for antiphospholipid syndrome and one (0.04%) for systemic sclerosis. In multiple exact logistic regression, after adjustment for potential confounders, the OR of overall complications of pregnancy were 2.81 (95% CI 1.29 to 6.18) in women with UCTD and 4.57 (95% CI 1.57 to 13.57) in those with definite diseases, respectively, compared with asymptomatic controls.CONCLUSIONS: In our population approximately 2.5% and 1% of first trimester pregnant women had a previously undiagnosed UCTD and definite systemic rheumatic disease, respectively. These conditions were associated with significant negative effects on the outcome of pregnancy.
Authors:
Arsenio Spinillo; Fausta Beneventi; Véronique Ramoni; Roberto Caporali; Elena Locatelli; Margherita Simonetta; Chiara Cavagnoli; Claudia Alpini; Giulia Albonico; Elena Prisco; Carlomaurizio Montecucco
Related Documents :
21458049 - Successful cryopreservation of expanded equine blastocysts.
22535759 - Maternal nutritional status in early pregnancy is associated with body water and plasma...
3739559 - Cervical cap homologous artificial insemination (aih): the university of florence exper...
2761149 - Transport of spermatozoa in the reproductive tract of the bitch: observations through u...
22574949 - Lifestyle interventions for overweight and obese pregnant women to improve pregnancy ou...
1554259 - Toxicity of construction materials in the marine environment: a comparison of chromated...
8272529 - Changes in oestrogen receptor protein, mrna expression and localization in the endometr...
8737659 - Sex ratios in fetuses and liveborn infants with autosomal aneuploidy.
272549 - The clinical significance of low urine oestriol values.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-30
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  -     ISSN:  1468-2060     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-2-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1Department of Obstetrics and Gynecology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential drug retention between anti-TNF agents and alternative biological agents after inadequa...
Next Document:  Comparative effectiveness and safety of biological treatment options after tumour necrosis factor ? ...